World Congress of Gastroenterology

WCOG 2019


 
Serum Spliceosome-associated protein 130 (SAP130) as A Novel Alarmin to Predict Disease Severity and the Clinical Efficacy of Exclusive Enteral Nutrition in Crohn’s Disease
WENBIN GONG 1 KUN GUO 2 JIANAN REN 3

1- SOUTHEAST UNIVERSITY
2- NANJING UNIVERSITY
3- JINLING HOSPITAL
 
Background/Aims:

Spliceosome-associated protein 130 (SAP130) is recognized as a proinflammatory damage-associated molecular pattern (DAMP) with a pathogenic role in several non-pathogen mediated inflammatory diseases. But its role in gut inflammation, particularly in Crohn’s disease (CD), remains unclear. The aim of this study was to analyze correlation between serum SAP130 level and disease severity, and to assess its predictive value for the clinical efficacy of exclusive enteral nutrition (EEN) in patients with active CD.

Materials and Methods:

Between August 2017 and January 2019, 73 consecutive CD patients (53 clinically active and 20 clinical remission) and 20 healthy control individuals were enrolled. Their serum SAP130 levels were measured. Correlations between the serum SAP130 levels and disease severity were evaluated. The colon tissue SAP130 and its receptor Mincle (macrophage-inducible C-type lectin) in active CD were measured for further exploration. Furthermore, the serum SAP130 level was investigated as a predictor of clinical efficacy in 40 patients treated with EEN within the group of 53 patients with active CD.

Results:

The serum SAP130 levels were significantly increased in the patients with active CD compared with remission CD patients (P < 0.001) and control individuals (P < 0.001), and they varied according to clinical activity and were significantly correlated to disease severity (all P < 0.05).  In parallel, the expressions of colon tissue SAP130 and Mincle both elevated in active CD. Additionally, the serum SAP130 level declined in patients with active CD who achieved efficacy at week 8 after EEN therapy. The areas under the curves for the SAP130 levels at the end of week 8 that could predict clinical remission and clinical response were 0.91 and 0.73, respectively.

Conclusion:

The preliminary evidence shows that SAP130 might be a potential noninvasive biomarker, which correlates well with disease severity and the clinical efficacy of EEN in CD.

Keywords:

spliceosome-associated protein 130; clinical efficacy; Crohns disease